Medication info
New Capen Capsule 75 mg (Pregabalin)

New Capen Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Kyungdong Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper and white lower part containing a white powder that is white or light yellow.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201804826 · Approved 2018.11.29 · Insurance code 648104160

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of pregabalin orally in two divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalinᵃ Starting dose (mg/day) | Maximum dose (mg/day) | Administration ≥60 | 150 | 600 | BID or TID ≥30-<60 | 75 | 300 | BID or TID ≥15-<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: The supplemental dose refers to an additional dose administered as a single dose. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4-hour hemodialysis session. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Use is not recommended. Adolescent patients aged 12-17 years: Use is not recommended.

Ingredients

Manufacturer
Kyungdong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used to alleviate peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures in epilepsy patients, whether or not accompanied by generalized symptoms. Lastly, it helps relieve pain in fibromyalgia patients. It is effectively used for the treatment of various neurological disorders.

How to take

Adult dose

Administer the total daily dose of pregabalin orally in two divided doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The initial dose may be 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalinᵃ Starting dose (mg/day) | Maximum dose (mg/day) | Administration ≥60 | 150 | 600 | BID or TID ≥30-<60 | 75 | 300 | BID or TID ≥15-<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under Administration. b: The supplemental dose refers to an additional dose administered as a single dose. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after every 4-hour hemodialysis session. 6. Patients with hepatic impairment No dose adjustment is required in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Use is not recommended. Adolescent patients aged 12-17 years: Use is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; therefore, if any symptoms of depression or mood changes occur during treatment, consult a healthcare professional immediately. Do not take this medication if you are allergic to any of its ingredients, and it should be avoided by patients with certain genetic metabolic disorders. Diabetic patients should be cautious as weight gain may necessitate dosage adjustment of blood sugar control medications. If hypersensitivity reactions such as angioedema occur, discontinue the medication immediately and inform your healthcare provider. Elderly patients may have an increased risk of falls due to dizziness or drowsiness, so particular caution is needed during the initiation of treatment. Transient visual disturbances or changes in vision may occur; consult a healthcare professional if symptoms persist. Withdrawal symptoms such as insomnia, headache, and anxiety can occur upon abrupt discontinuation, thus sudden cessation should be avoided. Patients with a history of substance abuse are at higher risk of misuse of this medication, so it should be taken cautiously, and signs of misuse should be closely monitored. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should take this medication with caution, and should inform their healthcare provider immediately if symptoms of heart failure occur. Caution is needed when taking with opioid analgesics due to increased risk of central nervous system depression. Patients with respiratory weakness or the elderly are at risk of severe respiratory suppression; therefore, dosage adjustment and monitoring are required. This medication should be avoided during early pregnancy due to the risk of fetal malformations, and fertile women should use effective contraception. During breastfeeding, this medication can be passed into breast milk, and safety has not been established; therefore, breastfeeding should be avoided or discussed with a healthcare professional. Caution is advised when driving or operating machinery due to the risk of accidents caused by dizziness and drowsiness. Severe skin reactions may rarely occur; discontinue usage immediately and inform your healthcare provider if any symptoms such as rash or swelling appear. In case of overdose, symptoms such as confusion, drowsiness, and seizures may occur; immediate medical attention is required, and treatments such as dialysis may be necessary.

Side effects

Suicidal ideation, suicidal behavior, depression, abnormal mood and behavioral changes, angioedema, facial edema, periorbital edema, upper respiratory tract edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, paraphilia, restlessness, anxiety, mood swings, emotional dysregulation, emotional elevation, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, apathy, ataxia, motor coordination disorders, balance disorders, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory disturbances, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, clonic contractions, decreased reflexes, movement disorders, psychomotor agitation, position-related dizziness, hypersensitivity, burning sensation, activity tremor, syncope, confusion, hypokinesia, olfactory disturbances, taste loss, writing impairment, blurred vision, diplopia, loss of indirect vision, visual disturbance, visual field loss, photopsia, dry eyes, conjunctival swelling, decreased vision, eye pain, eye fatigue, increased tear production, ocular irritation, mydriasis, vibration-related changes in visual depth perception, strabismus, brightness in vision, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, abdominal bloating, hypersalivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasm, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, mastopathy, peripheral edema, edema, gait abnormalities, falls, intoxicated feeling, sensory aberrations, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, congestive heart failure, pulmonary edema, nausea, diarrhea, lingual edema, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, mood disorders, drowsiness, confusional state, depression, agitation, restlessness, seizures, shock, anaphylaxis-like symptoms, skin and mucous membrane syndrome, erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. The appropriate storage temperature is between 15 to 30 degrees Celsius, and it should be kept in a location that is neither too hot nor too cold.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper and white lower part containing a white powder that is white or light yellow.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.